There are no reports of overdose cases. The nature of the drug Broncho-Vaxom® children's and the results of the study of its toxicity indicate that an overdose is unlikely.
Hypersensitivity to the components of the drug.
The drug can be used simultaneously with other drugs used in the treatment of acute and chronic respiratory diseases. Interaction with other drugs has not yet been established.
Gelatin capsules are solid size # 3, the lid is blue opaque, the body is white opaque, the contents are light beige powder.
Immunostimulating drug Broncho-Vaxom® children's is usually well tolerated. Most of the adverse reactions are classified as general with moderate or moderate severity. The most common manifestation of the side effect of the drug is a disorder of the gastrointestinal tract, skin reactions, respiratory disorders.
In each particular category, side effects are grouped by system-organ class and presented in descending order of frequency: very common (≥1/10), common (≥1/100 to <1/10), infrequent (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000), unknown (based on available data, it is impossible to evaluate).
From the gastrointestinal tract: often-diarrhea, abdominal pain, unknown-vomiting, nausea.
From the nervous system: unknown — headache.
From the respiratory system, chest and mediastinal organs: often-cough.
From the skin and subcutaneous tissue: often-rash, unknown - urticaria, Quincke's edema.
General disorders and disorders at the injection site: unknown — fever, fatigue.
From the immune system: infrequently-hypersensitivity (erythematous rash, generalized rash, erythema, edema of the eyelids, facial edema, peripheral edema, facial swelling, itching, generalized itching, shortness of breath).
Without a prescription.
Broncho-Wax® children's should not be used in children under the age of 6 months.
To avoid overdose, do not use the drug in the form of capsules intended for adults (Broncho-Vaxom® adult, capsules, 7 mg).
The components of the drug may cause hypersensitivity reactions.
In the case of persistent gastrointestinal disorders, skin reactions, respiratory disorders or other symptoms of intolerance to the drug, treatment should be discontinued, since these symptoms are a manifestation of allergic reactions.
Influence on the ability to drive vehicles and mechanisms. Broncho-Wax® children's does not affect the ability to drive vehicles and mechanisms.
The drug is used in children from 6 months to 12 years according to the following indications:
prevention of recurrent respiratory tract infection and exacerbations of chronic bronchitis,
complex treatment of acute respiratory tract infections.
Immunostimulating drug of bacterial origin. Causes an immune response of the mucous membrane of the digestive tract. The effect is particularly pronounced in Peyer's plaques (PB) of the small intestine. Antigen-presenting cells (APC) in PB are activated by the drug and subsequently stimulate cells responsible for specific immunity.
When using the drug, an increase in the number of circulating B-lymphocytes is observed.
After stimulation of B-lymphocytes, there is an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory mucosa and saliva.
These antibodies are the first line of defense against a range of infectious agents (viruses and bacteria).
The drug has a powerful stimulating effect on most types of white blood cells, as evidenced by an increase in the number of cells of the myeloid and lymphoid series, as well as a selective increase in the expression of receptors on their surface.
Taken together, these data confirm that the drug triggers biological reactions that enhance the body's immune defense against infection.
Clinically, Broncho-Wax® children's reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body's resistance to infections of the respiratory system. At the same time, the need for the use of other drugs, especially antibiotics, is reduced.
At a temperature of 15-25 °C.
Keep out of reach of children.
Shelf life of the drug Broncho-Vaxom® childlike5 лет. Не использовать по истечении срока годности, указанного на упаковке.Do not use after the expiration date indicated on the package.
| Gelatin capsules | 1 caps. |
| active substance: | |
| standardized lyophilizate of bacterial lysates (Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis) | 3.5 mg |
| (part of the lyophilisate of OM-85 — 20 mg) | |
| excipients: anhydrous propyl gallate (E310) - 0.042 mg, sodium glutamate-1.515 mg, mannitol-up to 20 mg, pre-gelatinized starch-110 mg, magnesium stearate-3 mg, mannitol-up to 200 mg | |
| capsule shell: dye indigocarmine (indigotine) (E132) - 0.01 mg, titanium dioxide (E171) — 1 mg, gelatin-the required amount up to 50 mg |
Capsules, 3.5 mg. In a blister of 10 pcs. 1 or 3 bl. in a pack of cardboard.
Inside.
Treatment: 1 capsule of the drug Broncho-Wax® children daily in the morning on an empty stomach until the symptoms disappear, but not less than 10 days. If necessary, antibiotic therapy with Broncho-Wax® children should be taken in combination with an antibiotic from the beginning of treatment.
The duration of treatment or the appointment of a second course of therapy should be determined by the doctor, based on the patient's state of health.
Prevention of exacerbations and maintenance therapy: 1 capsule of the drug Broncho-Wax® children's daily morning on an empty stomach. The course includes 3 cycles, each of which consists of a daily intake of 1 capsule for 10 days, the interval between cycles is 20 days.
If the capsule is difficult to swallow, it should be opened and mixed with the contents of the drink (including fruit juice, milk).
L03A Immunostimulants
